Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah L Tumbrink

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Oncogene|October 16, 2020
The next tier of EGFR resistance mutations in lung cancerHannah L Tumbrink, Alena Heimsoeth, Martin L Sos
Journal of Medicinal Chemistry|June 13, 2017
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding SiteMarcel Günther, Jonas Lategahn, Michael Juchum, et al.
Journal of Medicinal Chemistry|February 23, 2017
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor ReceptorStefano Tomassi, Jonas Lategahn, Julian Engel, et al.
Bioconjugate Chemistry|June 22, 2018
Insights into the Kinetics of the Resistance Formation of Bacteria against Ciprofloxacin Poly(2-methyl-2-oxazoline) ConjugatesMartin Schmidt, Alina Romanovska, Youssef Wolf, et al.
Journal of Medicinal Chemistry|August 31, 2017
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor ReceptorJulian Engel, Steven Smith, Jonas Lategahn, et al.
Molecular Cancer Therapeutics|March 5, 2022
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationLisa Werr, Dennis Plenker, Marcel A Dammert, et al.
Journal of Medicinal Chemistry|September 15, 2020
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design ApproachJonas Lategahn, Julia Hardick, Tobias Grabe, et al.
Nature Communications|April 7, 2021
Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypesChristina M Bebber, Emily S Thomas, Jenny Stroh, et al.
Journal of Medicinal Chemistry|April 29, 2022
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsJonas Lategahn, Hannah L Tumbrink, Carsten Schultz-Fademrecht, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Oncogene|October 16, 2020
The next tier of EGFR resistance mutations in lung cancerHannah L Tumbrink, Alena Heimsoeth, Martin L Sos
Journal of Medicinal Chemistry|June 13, 2017
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding SiteMarcel Günther, Jonas Lategahn, Michael Juchum, et al.
Journal of Medicinal Chemistry|February 23, 2017
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor ReceptorStefano Tomassi, Jonas Lategahn, Julian Engel, et al.
Bioconjugate Chemistry|June 22, 2018
Insights into the Kinetics of the Resistance Formation of Bacteria against Ciprofloxacin Poly(2-methyl-2-oxazoline) ConjugatesMartin Schmidt, Alina Romanovska, Youssef Wolf, et al.
Journal of Medicinal Chemistry|August 31, 2017
Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor ReceptorJulian Engel, Steven Smith, Jonas Lategahn, et al.
Molecular Cancer Therapeutics|March 5, 2022
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationLisa Werr, Dennis Plenker, Marcel A Dammert, et al.
Journal of Medicinal Chemistry|September 15, 2020
Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design ApproachJonas Lategahn, Julia Hardick, Tobias Grabe, et al.
Nature Communications|April 7, 2021
Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypesChristina M Bebber, Emily S Thomas, Jenny Stroh, et al.
Journal of Medicinal Chemistry|April 29, 2022
Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing InhibitorsJonas Lategahn, Hannah L Tumbrink, Carsten Schultz-Fademrecht, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
Pageof 2